Youluyanglu的个人主页 - 老虎社区

Youluyanglu

Youluyanglu

右禄阳禄

IP属地：未知

49关注

13粉丝

0主题

0勋章

2021-07-27

This is a no brained stock to hold and long[Miser] [Miser] [Miser] [Miser]

Tesla Is a Mature Business. Don’t Look Now.<blockquote>特斯拉是一项成熟的业务。现在别看。</blockquote>

2021-08-03

What. ePS?

Nikola Q2 adj. per-share loss 20 cents, beats loss 30 cents estimate<blockquote>尼古拉Q2调整后。每股亏损20美分，超出预期30美分</blockquote>

2021-11-01

Tesla will soon go for split again

2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>

2021-07-27

Sales surge 98%???? Will stock price surge 10%????

Tesla shares rose more than 1% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨超过1%</blockquote>

2021-07-27

$Palantir Technologies Inc.(PLTR)$Always down most trading day, never up to $30 [Angry] [Angry] [Angry] [Angry]

2021-11-13

$BioNTech SE(BNTX)$Is this a falling knife stock?

2021-10-23

Buy and treat as fixed deposit worry free stock

S&P Says Tesla Inc. Upgraded To 'BB+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive<blockquote>标准普尔表示，由于强劲的需求前景和稳健的财务指标，特斯拉公司将评级上调至“BB+”；展望积极</blockquote>

2021-09-29

But yesterday drop more then today little increase [Spurting] [Spurting] [Spurting]

Pharmaceutical stocks rallied in morning trading<blockquote>医药股早盘上涨</blockquote>

2021-06-26

$Tesla Motors(TSLA)$Bitcoin down Tesla down damn unlucky coin[Sad] [Sad] [Sad] [Sad] [Sad] [Sad] [Speechless] [Sad] [Sad] [Sad]

2021-10-02

Her ETF is under performance after bill haung and her partner left .

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3560307510640662","uuid":"3560307510640662","gmtCreate":1597299768333,"gmtModify":1635040009566,"name":"Youluyanglu","pinyin":"youluyanglu","introduction":"","introductionEn":"","signature":"右禄阳禄","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":13,"headSize":49,"tweetSize":154,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.13","exceedPercentage":"93.32%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":690867711,"gmtCreate":1639656223902,"gmtModify":1639656224098,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"Selling from high to low? How intelligent sheis!","listText":"Selling from high to low? How intelligent sheis!","text":"Selling from high to low? How intelligent sheis!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690867711","repostId":"1191022113","repostType":2,"repost":{"id":"1191022113","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639626011,"share":"https://www.laohu8.com/m/news/1191022113?lang=zh_CN&edition=full","pubTime":"2021-12-16 11:40","market":"us","language":"en","title":"Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191022113","media":"Benzinga","summary":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — i","content":"<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p><p><blockquote><b>凯西·伍德</b>-led<b>方舟投资</b>周三出售了90,455股股票，估计价值8830万美元<b>特斯拉公司</b>，该股在连续几天下跌后上涨时获利了结。</blockquote></p><p> The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p><p><blockquote>该股周三收高1.82%，收于每股975.99美元。这家埃隆·马斯克(Elon Musk)领导的公司股价今年迄今上涨了约34%，过去一个月下跌了约7.5%。</blockquote></p><p> Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p><p><blockquote>Ark Invest通过<b>方舟创新ETF</b>（蝙蝠：ARKK），<b>Ark自主技术与机器人ETF</b>（蝙蝠：ARKQ）和<b>方舟下一代互联网ETF</b>（蝙蝠：ARKW）周三。</blockquote></p><p> Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p><p><blockquote>在周三交易之前，特斯拉在ARKK和ARKW的权重已经跌破10%的门槛，分别为8.14%和9.35%。在ARKQ中，它占投资组合的10.59%。</blockquote></p><p> The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p><p><blockquote>在周三交易之前，这三只ETF持有特斯拉199万股股票，价值19.1亿美元。</blockquote></p><p> Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p><p><blockquote>Ark Invest自9月份以来一直在特斯拉获利，出售了价值超过30亿美元的股票，此前多年来一直在这家电动汽车公司的股票处于低得多的水平。</blockquote></p><p> Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p><p><blockquote>特斯拉仍然是该公司在ETF中最大的押注——预计该股到2025年底将触及3,000美元大关。</blockquote></p><p> Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p><p><blockquote>伍德支持汽车行业转向电动汽车，并于本月早些时候开始购买这家在美国上市的中国电动汽车制造商的股票<b>小鹏汽车</b>.</blockquote></p><p> Here are the other key trades on Wednesday:</p><p><blockquote>以下是周三的其他关键交易：</blockquote></p><p> <ul>  <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>  <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li> </ul></p><p><blockquote><ul><li>购买了104,489股股票，估计价值2,130万美元<b>Roku公司</b>在下降。该股周三收盘下跌7.95%，至每股203.94美元。</li><li>购买了705,660股股票，估计价值1,370万美元<b>罗宾汉市场公司</b>该股收涨1.93%，报每股19.50美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-16 11:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p><p><blockquote><b>凯西·伍德</b>-led<b>方舟投资</b>周三出售了90,455股股票，估计价值8830万美元<b>特斯拉公司</b>，该股在连续几天下跌后上涨时获利了结。</blockquote></p><p> The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p><p><blockquote>该股周三收高1.82%，收于每股975.99美元。这家埃隆·马斯克(Elon Musk)领导的公司股价今年迄今上涨了约34%，过去一个月下跌了约7.5%。</blockquote></p><p> Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p><p><blockquote>Ark Invest通过<b>方舟创新ETF</b>（蝙蝠：ARKK），<b>Ark自主技术与机器人ETF</b>（蝙蝠：ARKQ）和<b>方舟下一代互联网ETF</b>（蝙蝠：ARKW）周三。</blockquote></p><p> Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p><p><blockquote>在周三交易之前，特斯拉在ARKK和ARKW的权重已经跌破10%的门槛，分别为8.14%和9.35%。在ARKQ中，它占投资组合的10.59%。</blockquote></p><p> The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p><p><blockquote>在周三交易之前，这三只ETF持有特斯拉199万股股票，价值19.1亿美元。</blockquote></p><p> Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p><p><blockquote>Ark Invest自9月份以来一直在特斯拉获利，出售了价值超过30亿美元的股票，此前多年来一直在这家电动汽车公司的股票处于低得多的水平。</blockquote></p><p> Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p><p><blockquote>特斯拉仍然是该公司在ETF中最大的押注——预计该股到2025年底将触及3,000美元大关。</blockquote></p><p> Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p><p><blockquote>伍德支持汽车行业转向电动汽车，并于本月早些时候开始购买这家在美国上市的中国电动汽车制造商的股票<b>小鹏汽车</b>.</blockquote></p><p> Here are the other key trades on Wednesday:</p><p><blockquote>以下是周三的其他关键交易：</blockquote></p><p> <ul>  <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>  <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li> </ul></p><p><blockquote><ul><li>购买了104,489股股票，估计价值2,130万美元<b>Roku公司</b>在下降。该股周三收盘下跌7.95%，至每股203.94美元。</li><li>购买了705,660股股票，估计价值1,370万美元<b>罗宾汉市场公司</b>该股收涨1.93%，报每股19.50美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HOOD":"Robinhood","ARKK":"ARK Innovation ETF","XPEV":"小鹏汽车","ARKW":"ARK Next Generation Internet ETF","ROKU":"Roku Inc","ARKQ":"ARK Autonomous Technology & Robotics ETF","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191022113","content_text":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in Tesla Inc, booking profit in the stock as it rose after days of losses.\nThe stock pared earlier losses to close 1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.\nArk Invest sold the shares via the Ark Innovation ETF(BATS:ARKK), the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ) and the Ark Next Generation Internet ETF(BATS:ARKW) on Wednesday.\nTesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.\nThe three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.\nArk Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.\nTesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the $3,000 mark by the end of 2025.\nWood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker Xpeng Inc.\nHere are the other key trades on Wednesday:\n\nBought 104,489 shares — estimated to be worth $21.3 million — in Roku Inc on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.\nBought 705,660 shares — estimated to be worth $13.7 million — in Robinhood Markets Inc. The stock closed 1.93% higher at $19.50 a share.","news_type":1,"symbols_score_info":{"HOOD":0.9,"XPEV":0.9,"ROKU":0.9,"ARKK":0.9,"TSLA":0.9,"ARKQ":0.9,"ARKW":0.9}},"isVote":1,"tweetType":1,"viewCount":2351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601930357,"gmtCreate":1638474281404,"gmtModify":1638474281483,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TDOC\">$Teladoc Health Inc.(TDOC)$</a>Next week 85?","listText":"<a href=\"https://laohu8.com/S/TDOC\">$Teladoc Health Inc.(TDOC)$</a>Next week 85?","text":"$Teladoc Health Inc.(TDOC)$Next week 85?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601930357","isVote":1,"tweetType":1,"viewCount":2037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601070729,"gmtCreate":1638463935686,"gmtModify":1638463935807,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"Why didn’t you bought Charlie munger’s baba stock???","listText":"Why didn’t you bought Charlie munger’s baba stock???","text":"Why didn’t you bought Charlie munger’s baba stock???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601070729","repostId":"2188124518","repostType":4,"isVote":1,"tweetType":1,"viewCount":2165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603800079,"gmtCreate":1638385669067,"gmtModify":1638385669311,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TDOC\">$Teladoc Health Inc.(TDOC)$</a>Anymore hope?!?!","listText":"<a href=\"https://laohu8.com/S/TDOC\">$Teladoc Health Inc.(TDOC)$</a>Anymore hope?!?!","text":"$Teladoc Health Inc.(TDOC)$Anymore hope?!?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603800079","isVote":1,"tweetType":1,"viewCount":2502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600775661,"gmtCreate":1638201955405,"gmtModify":1638201955677,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Luckily run at 364","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Luckily run at 364","text":"$BioNTech SE(BNTX)$Luckily run at 364","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600775661","isVote":1,"tweetType":1,"viewCount":2582,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875420854,"gmtCreate":1637679875594,"gmtModify":1637679875672,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>Production no scalibity how to fill the world","listText":"<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>Production no scalibity how to fill the world","text":"$Rivian Automotive, Inc.(RIVN)$Production no scalibity how to fill the world","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875420854","isVote":1,"tweetType":1,"viewCount":2806,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875366490,"gmtCreate":1637611062173,"gmtModify":1637611062289,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"We","listText":"We","text":"We","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875366490","repostId":"876938585","repostType":1,"repost":{"id":876938585,"gmtCreate":1637248228670,"gmtModify":1637248228670,"author":{"id":"3575447170954511","authorId":"3575447170954511","name":"WolfofWS","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575447170954511","authorIdStr":"3575447170954511"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TDOC\">$Teladoc Health Inc.(TDOC)$</a>What is wrong? [Facepalm]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TDOC\">$Teladoc Health Inc.(TDOC)$</a>What is wrong? [Facepalm]&nbsp;","text":"$Teladoc Health Inc.(TDOC)$What is wrong? [Facepalm]","images":[{"img":"https://static.tigerbbs.com/a20c9170ef82c95a2aabb86d2f33e2e2","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876938585","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875002198,"gmtCreate":1637583776456,"gmtModify":1637583776537,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>Luckily I sold all one month plus at $8 after d c a.","listText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>Luckily I sold all one month plus at $8 after d c a.","text":"$Clover Health Corp(CLOV)$Luckily I sold all one month plus at $8 after d c a.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875002198","isVote":1,"tweetType":1,"viewCount":2327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876318570,"gmtCreate":1637265183332,"gmtModify":1637265183332,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"Lesser Tesla stock low chance to win","listText":"Lesser Tesla stock low chance to win","text":"Lesser Tesla stock low chance to win","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876318570","repostId":"852866819","repostType":1,"repost":{"id":852866819,"gmtCreate":1635257597351,"gmtModify":1635257598523,"author":{"id":"3567070024174374","authorId":"3567070024174374","name":"TrisT","avatar":"https://static.tigerbbs.com/8ed7f4b6aa33dc3d4922b2cf0b507be0","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567070024174374","authorIdStr":"3567070024174374"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ARKW\">$ARK Next Generation Internet ETF(ARKW)$</a>after months , it finally break even","listText":"<a href=\"https://laohu8.com/S/ARKW\">$ARK Next Generation Internet ETF(ARKW)$</a>after months , it finally break even","text":"$ARK Next Generation Internet ETF(ARKW)$after months , it finally break even","images":[{"img":"https://static.tigerbbs.com/27a0f680abfb481d14cfd4e0ba40e639","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852866819","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2507,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876318301,"gmtCreate":1637264967185,"gmtModify":1637264967303,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ROKU\">$Roku Inc(ROKU)$</a>Where is the most for this share?","listText":"<a href=\"https://laohu8.com/S/ROKU\">$Roku Inc(ROKU)$</a>Where is the most for this share?","text":"$Roku Inc(ROKU)$Where is the most for this share?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876318301","isVote":1,"tweetType":1,"viewCount":2127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879510105,"gmtCreate":1636735552212,"gmtModify":1636754295246,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Hood q3earnings still fall like bird shit[Surprised]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Hood q3earnings still fall like bird shit[Surprised]&nbsp;","text":"$Palantir Technologies Inc.(PLTR)$Hood q3earnings still fall like bird shit[Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879510105","isVote":1,"tweetType":1,"viewCount":509,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879532663,"gmtCreate":1636734917800,"gmtModify":1636734917915,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Is this a falling knife stock?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Is this a falling knife stock?","text":"$BioNTech SE(BNTX)$Is this a falling knife stock?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/879532663","isVote":1,"tweetType":1,"viewCount":1985,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870781069,"gmtCreate":1636647401926,"gmtModify":1636647402185,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPNG\">$Coupang, Inc.(CPNG)$</a>All the way down ever since IPO","listText":"<a href=\"https://laohu8.com/S/CPNG\">$Coupang, Inc.(CPNG)$</a>All the way down ever since IPO","text":"$Coupang, Inc.(CPNG)$All the way down ever since IPO","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870781069","isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847797922,"gmtCreate":1636552907903,"gmtModify":1636553012053,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"Burry should try not drawing salary and bonus for 10 years before he commented this.","listText":"Burry should try not drawing salary and bonus for 10 years before he commented this.","text":"Burry should try not drawing salary and bonus for 10 years before he commented this.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847797922","repostId":"1180704879","repostType":2,"isVote":1,"tweetType":1,"viewCount":837,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842334997,"gmtCreate":1636131742639,"gmtModify":1636131742913,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Giga Austin fast progresss","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Giga Austin fast progresss","text":"$Tesla Motors(TSLA)$Giga Austin fast progresss","images":[{"img":"https://static.tigerbbs.com/35061c7b33e3fd86a3ac589da0815aba","width":"2000","height":"1125"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842334997","isVote":1,"tweetType":1,"viewCount":601,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848720805,"gmtCreate":1636031169593,"gmtModify":1636031502532,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"Nikola got result!?!","listText":"Nikola got result!?!","text":"Nikola got result!?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848720805","repostId":"1100949235","repostType":4,"repost":{"id":"1100949235","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636031029,"share":"https://www.laohu8.com/m/news/1100949235?lang=zh_CN&edition=full","pubTime":"2021-11-04 21:03","market":"us","language":"en","title":"Nikola stock surged 6% after reporting quarterly results<blockquote>尼古拉公布季度业绩后股价飙升6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100949235","media":"Tiger Newspress","summary":"Nikola stock surged 6% after reporting quarterly results.\n\nNikola Corporation today reported financi","content":"<p>Nikola stock surged 6% after reporting quarterly results.</p><p><blockquote>Nikola公布季度业绩后股价飙升6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/eed83deb9bd3d57a85bf31a9ee1b16d7\" tg-width=\"849\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Nikola Corporation&nbsp;today reported financial results for the quarter ended September 30, 2021.</p><p><blockquote>尼古拉公司今天公布了截至2021年9月30日的季度财务业绩。</blockquote></p><p> <ul>  <li>Up to 25 Tre BEV trucks are expected to be delivered to dealers and customers by the end of 2021 and Tre FCEV is on schedule, and testing has begun</p><p><blockquote><ul><li>预计到2021年底将向经销商和客户交付多达25辆Tre BEV卡车，Tre FCEV按计划进行，测试已开始</li></ul></blockquote></p><p></li>  <li>Continued progress building out the sales and service network with dealers in 28 states consisting of over 130 locations</p><p><blockquote><li>继续在28个州建立销售和服务网络，经销商遍布130多个地点</li></blockquote></p><p></li>  <li>Ulm, Germany joint venture manufacturing facility inaugurated in September</p><p><blockquote><li>德国乌尔姆合资制造工厂于九月落成</li></blockquote></p><p></li>  <li>$125 million reserved to fund potential settlement with the SEC</p><p><blockquote><li>预留1.25亿美元用于资助与SEC的潜在和解</li></blockquote></p><p></li> </ul> \"During the third quarter, we continued to execute on our business plan,” said Mark Russell, Nikola's Chief Executive Officer. “Validation of the Nikola Tre BEV is progressing, with trucks now being test-driven and tested on public roads. We also formally inaugurated our joint venture manufacturing facility in Ulm, Germany, and entered into additional strategic partnerships to advance our hydrogen refueling ecosystem with TC Energy and OPAL Fuels.”</p><p><blockquote>Nikola首席执行官Mark Russell表示：“第三季度，我们继续执行我们的业务计划。Nikola Tre BEV的验证正在取得进展，卡车现在正在公共道路上进行试驾和测试。我们还正式启动了位于德国乌尔姆的合资制造工厂，并与TC Energy和OPAL Fuels建立了额外的战略合作伙伴关系，以推进我们的加氢生态系统。”</blockquote></p><p> Russell added, “with prospects of an SEC settlement, we’re looking forward to resolving the outstanding issues relating to our founder and bringing that chapter to a close and maintaining our focus on delivering trucks to our customers, and building the energy, service, and support infrastructure our customers need.”</p><p><blockquote>拉塞尔补充道：“随着美国证券交易委员会达成和解的前景，我们期待解决与我们创始人相关的悬而未决的问题，结束这一篇章，并继续专注于向客户交付卡车，以及建设能源、服务和支持我们的客户所需的基础设施。”</blockquote></p><p> <b>Third Quarter Financial Highlights</b></p><p><blockquote><b>第三季度财务摘要</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/0c6af9593f60adb9a4fa204669090164\" tg-width=\"2994\" tg-height=\"960\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Business Outlook</b></p><p><blockquote><b>业务展望</b></blockquote></p><p> Nikola looks forward to achieving the following milestones in the fourth quarter of 2021:</p><p><blockquote>尼古拉期待在2021年第四季度实现以下里程碑：</blockquote></p><p> <ul>  <li>Deliver pre-series Nikola Tre BEVs for use on public roads hauling customer freight;</p><p><blockquote><ul><li>交付预系列Nikola Tre纯电动汽车，用于在公共道路上运输客户货物；</li></ul></blockquote></p><p></li>  <li>Announce additional fleet testing dealers/customers;</p><p><blockquote><li>宣布额外的车队测试经销商/客户；</li></blockquote></p><p></li>  <li>Purchase land for our first centralized hydrogen production hub facility and/or commercial on-site gaseous generation station; and</p><p><blockquote><li>为我们的首个集中制氢中心设施及╱或商业现场气体发电站购买土地；和</li></blockquote></p><p></li>  <li>Announce additional hydrogen infrastructure/ecosystem partners</p><p><blockquote><li>宣布更多氢基础设施/生态系统合作伙伴</li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nikola stock surged 6% after reporting quarterly results<blockquote>尼古拉公布季度业绩后股价飙升6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNikola stock surged 6% after reporting quarterly results<blockquote>尼古拉公布季度业绩后股价飙升6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-04 21:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Nikola stock surged 6% after reporting quarterly results.</p><p><blockquote>Nikola公布季度业绩后股价飙升6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/eed83deb9bd3d57a85bf31a9ee1b16d7\" tg-width=\"849\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Nikola Corporation&nbsp;today reported financial results for the quarter ended September 30, 2021.</p><p><blockquote>尼古拉公司今天公布了截至2021年9月30日的季度财务业绩。</blockquote></p><p> <ul>  <li>Up to 25 Tre BEV trucks are expected to be delivered to dealers and customers by the end of 2021 and Tre FCEV is on schedule, and testing has begun</p><p><blockquote><ul><li>预计到2021年底将向经销商和客户交付多达25辆Tre BEV卡车，Tre FCEV按计划进行，测试已开始</li></ul></blockquote></p><p></li>  <li>Continued progress building out the sales and service network with dealers in 28 states consisting of over 130 locations</p><p><blockquote><li>继续在28个州建立销售和服务网络，经销商遍布130多个地点</li></blockquote></p><p></li>  <li>Ulm, Germany joint venture manufacturing facility inaugurated in September</p><p><blockquote><li>德国乌尔姆合资制造工厂于九月落成</li></blockquote></p><p></li>  <li>$125 million reserved to fund potential settlement with the SEC</p><p><blockquote><li>预留1.25亿美元用于资助与SEC的潜在和解</li></blockquote></p><p></li> </ul> \"During the third quarter, we continued to execute on our business plan,” said Mark Russell, Nikola's Chief Executive Officer. “Validation of the Nikola Tre BEV is progressing, with trucks now being test-driven and tested on public roads. We also formally inaugurated our joint venture manufacturing facility in Ulm, Germany, and entered into additional strategic partnerships to advance our hydrogen refueling ecosystem with TC Energy and OPAL Fuels.”</p><p><blockquote>Nikola首席执行官Mark Russell表示：“第三季度，我们继续执行我们的业务计划。Nikola Tre BEV的验证正在取得进展，卡车现在正在公共道路上进行试驾和测试。我们还正式启动了位于德国乌尔姆的合资制造工厂，并与TC Energy和OPAL Fuels建立了额外的战略合作伙伴关系，以推进我们的加氢生态系统。”</blockquote></p><p> Russell added, “with prospects of an SEC settlement, we’re looking forward to resolving the outstanding issues relating to our founder and bringing that chapter to a close and maintaining our focus on delivering trucks to our customers, and building the energy, service, and support infrastructure our customers need.”</p><p><blockquote>拉塞尔补充道：“随着美国证券交易委员会达成和解的前景，我们期待解决与我们创始人相关的悬而未决的问题，结束这一篇章，并继续专注于向客户交付卡车，以及建设能源、服务和支持我们的客户所需的基础设施。”</blockquote></p><p> <b>Third Quarter Financial Highlights</b></p><p><blockquote><b>第三季度财务摘要</b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/0c6af9593f60adb9a4fa204669090164\" tg-width=\"2994\" tg-height=\"960\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Business Outlook</b></p><p><blockquote><b>业务展望</b></blockquote></p><p> Nikola looks forward to achieving the following milestones in the fourth quarter of 2021:</p><p><blockquote>尼古拉期待在2021年第四季度实现以下里程碑：</blockquote></p><p> <ul>  <li>Deliver pre-series Nikola Tre BEVs for use on public roads hauling customer freight;</p><p><blockquote><ul><li>交付预系列Nikola Tre纯电动汽车，用于在公共道路上运输客户货物；</li></ul></blockquote></p><p></li>  <li>Announce additional fleet testing dealers/customers;</p><p><blockquote><li>宣布额外的车队测试经销商/客户；</li></blockquote></p><p></li>  <li>Purchase land for our first centralized hydrogen production hub facility and/or commercial on-site gaseous generation station; and</p><p><blockquote><li>为我们的首个集中制氢中心设施及╱或商业现场气体发电站购买土地；和</li></blockquote></p><p></li>  <li>Announce additional hydrogen infrastructure/ecosystem partners</p><p><blockquote><li>宣布更多氢基础设施/生态系统合作伙伴</li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100949235","content_text":"Nikola stock surged 6% after reporting quarterly results.\n\nNikola Corporation today reported financial results for the quarter ended September 30, 2021.\n\nUp to 25 Tre BEV trucks are expected to be delivered to dealers and customers by the end of 2021 and Tre FCEV is on schedule, and testing has begun\nContinued progress building out the sales and service network with dealers in 28 states consisting of over 130 locations\nUlm, Germany joint venture manufacturing facility inaugurated in September\n$125 million reserved to fund potential settlement with the SEC\n\n\"During the third quarter, we continued to execute on our business plan,” said Mark Russell, Nikola's Chief Executive Officer. “Validation of the Nikola Tre BEV is progressing, with trucks now being test-driven and tested on public roads. We also formally inaugurated our joint venture manufacturing facility in Ulm, Germany, and entered into additional strategic partnerships to advance our hydrogen refueling ecosystem with TC Energy and OPAL Fuels.”\nRussell added, “with prospects of an SEC settlement, we’re looking forward to resolving the outstanding issues relating to our founder and bringing that chapter to a close and maintaining our focus on delivering trucks to our customers, and building the energy, service, and support infrastructure our customers need.”\nThird Quarter Financial Highlights\n\nBusiness Outlook\nNikola looks forward to achieving the following milestones in the fourth quarter of 2021:\n\nDeliver pre-series Nikola Tre BEVs for use on public roads hauling customer freight;\nAnnounce additional fleet testing dealers/customers;\nPurchase land for our first centralized hydrogen production hub facility and/or commercial on-site gaseous generation station; and\nAnnounce additional hydrogen infrastructure/ecosystem partners","news_type":1,"symbols_score_info":{"NKLA":0.9}},"isVote":1,"tweetType":1,"viewCount":867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849653182,"gmtCreate":1635754370904,"gmtModify":1635754371016,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Next Monday or Tuesday Tesla board meeting. If this week the price reach 1250 high chance will split&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Next Monday or Tuesday Tesla board meeting. If this week the price reach 1250 high chance will split&nbsp;","text":"$Tesla Motors(TSLA)$Next Monday or Tuesday Tesla board meeting. If this week the price reach 1250 high chance will split","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/849653182","isVote":1,"tweetType":1,"viewCount":1120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849880282,"gmtCreate":1635742012878,"gmtModify":1635742012952,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"Tesla will soon go for split again","listText":"Tesla will soon go for split again","text":"Tesla will soon go for split again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/849880282","repostId":"1164035523","repostType":2,"repost":{"id":"1164035523","kind":"news","pubTimestamp":1635736469,"share":"https://www.laohu8.com/m/news/1164035523?lang=zh_CN&edition=full","pubTime":"2021-11-01 11:14","market":"us","language":"en","title":"2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164035523","media":"Motley Fool","summary":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders h","content":"<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场寻求资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-01 11:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场寻求资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SENS":"Senseonics Holdings,Inc.","MREO":"Mereo Biopharma Group Plc"},"source_url":"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164035523","content_text":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points.\nWhich stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist Mereo BioPharma Group(NASDAQ:MREO)and the diabetes-focused medical device company Senseonics Holdings(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced healthcare stocks have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.\nHere's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.\nMereo BioPharma: A bet on the future of immunotherapy\nThe London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.\nWhat's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the anti-TIGIT therapy known as etigilimab. Several major drug companies, such as BeiGene,Bristol Myers Squibb,Merck, and Roche, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.\nAs things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.\nWhat's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.\nSenseonic: A rising tide lifts all boats\nSenseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10% per year over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.\nSo far, Senseonics has only captured a small sliver of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.\nWhy does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from DexCom and Abbott Laboratories, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.\nWhat's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.\nAll told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.","news_type":1,"symbols_score_info":{"MREO":0.9,"SENS":0.9}},"isVote":1,"tweetType":1,"viewCount":952,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857870612,"gmtCreate":1635519638118,"gmtModify":1635519638233,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPNG\">$Coupang, Inc.(CPNG)$</a>Loser stock always down seldom up","listText":"<a href=\"https://laohu8.com/S/CPNG\">$Coupang, Inc.(CPNG)$</a>Loser stock always down seldom up","text":"$Coupang, Inc.(CPNG)$Loser stock always down seldom up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857870612","isVote":1,"tweetType":1,"viewCount":834,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854621930,"gmtCreate":1635451859234,"gmtModify":1635451859447,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3560307510640662","authorIdStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Donkey ETF everydaytrimming[Spurting]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Donkey ETF everydaytrimming[Spurting]&nbsp;","text":"$Tesla Motors(TSLA)$Donkey ETF everydaytrimming[Spurting]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854621930","isVote":1,"tweetType":1,"viewCount":792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":803056668,"gmtCreate":1627397857754,"gmtModify":1631893653628,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"This is a no brained stock to hold and long[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","listText":"This is a no brained stock to hold and long[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","text":"This is a no brained stock to hold and long[Miser] [Miser] [Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/803056668","repostId":"1124516451","repostType":4,"repost":{"id":"1124516451","kind":"news","pubTimestamp":1627397263,"share":"https://www.laohu8.com/m/news/1124516451?lang=zh_CN&edition=full","pubTime":"2021-07-27 22:47","market":"us","language":"en","title":"Tesla Is a Mature Business. Don’t Look Now.<blockquote>特斯拉是一项成熟的业务。现在别看。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124516451","media":"Barrons","summary":"The electric-vehicle company Tesla reported its best quarterly results ever Monday evening, but investors and analysts are greeting the news with measured optimism—a sign that Tesla is maturing as a company.Tesla  reported $1.45 in adjusted per-share earnings for the second quarter, far higher than the roughly 95 cents analysts were looking for. Sales from regulatory credits—a source of revenue seen as less sustainable than sales of vehicles—-fell, but operating profits rose to record highs beca","content":"<p>The electric-vehicle company&nbsp;Tesla&nbsp;reported its&nbsp;best quarterly results&nbsp;ever Monday evening, but investors and analysts are greeting the news with measured optimism—a sign that Tesla is maturing as a company.</p><p><blockquote>电动汽车公司特斯拉周一晚间公布了有史以来最好的季度业绩，但投资者和分析师对这一消息持谨慎乐观的态度——这表明特斯拉作为一家公司正在走向成熟。</blockquote></p><p> Tesla (ticker: TSLA)&nbsp;reported&nbsp;$1.45 in adjusted per-share earnings for the second quarter, far higher than the roughly 95 cents analysts were looking for. Sales from regulatory credits—a source of revenue seen as less sustainable than sales of vehicles—-fell, but operating profits rose to record highs because of strong profitability in the automotive division.</p><p><blockquote>特斯拉（股票代码：TSLA）公布第二季度调整后每股收益为1.45美元，远高于分析师预期的约95美分。监管信贷的销售额——一种被认为不如汽车销售可持续的收入来源——下降了，但由于汽车部门的强劲盈利能力，营业利润升至历史新高。</blockquote></p><p> Tesla generates the credits by making more than its fair share of zero- emission cars and sells them to manufacturers that still rely on internal-combustion engines. Pessimists on the stock believe that source of income will dwindle over time.</p><p><blockquote>特斯拉通过生产超过其公平份额的零排放汽车并将其出售给仍然依赖内燃机的制造商来产生积分。该股的悲观主义者认为，随着时间的推移，收入来源将会减少。</blockquote></p><p> The stock, however, was down 1.5% in early trading Tuesday. The&nbsp;S&amp;P 500&nbsp;and&nbsp;Dow Jones Industrial Average,for comparison, had fallen 0.6% and 0.4%, respectively.</p><p><blockquote>然而，该股周二早盘下跌1.5%。相比之下，标准普尔500指数和道琼斯工业平均指数分别下跌0.6%和0.4%。</blockquote></p><p> It is a muted reaction to a good quarter, typical of the way stocks of mature businesses behave. Tesla stock moved more than 10% in response to three of the four 2019 quarterly reports. But it rose or fell an average of about 2.5% in response to the 2020 earnings reports.</p><p><blockquote>这是对良好季度的温和反应，是成熟企业股票的典型表现。特斯拉股价因2019年四份季度报告中的三份而上涨超过10%。但随着2020年收益报告的发布，该指数平均上涨或下跌约2.5%。</blockquote></p><p> The typical 2020 move was a fall in the price in response to news of better-than-expected results. The same thing happened after the release of results for the first quarter of 2021.</p><p><blockquote>2020年的典型走势是因业绩好于预期的消息而导致价格下跌。同样的事情发生在2021年第一季度业绩发布后。</blockquote></p><p> That is another sign of maturity. A small drop in response to better-than-expected results is the typical outcome for stocks. Investors always expect companies to exceed analyst projections, and when they get that result, they “sell the news.”</p><p><blockquote>这是成熟的另一个标志。由于业绩好于预期而小幅下跌是股市的典型结果。投资者总是期望公司超出分析师的预测，当他们得到这个结果时，他们就会“卖出消息”。</blockquote></p><p> The reaction among Wall Street analysts to the latest results is yet another sign of maturity. Mizuho analyst&nbsp;Vijay Rakesh&nbsp;raised his target for Tesla’s stock price by $5 to $825 following the news, for a bump of less than 1%.</p><p><blockquote>华尔街分析师对最新业绩的反应是成熟的又一个迹象。消息传出后，瑞穗分析师Vijay Rakesh将特斯拉股价目标上调5美元至825美元，涨幅不到1%。</blockquote></p><p> Back in January, RBC analyst&nbsp;Joe Spak&nbsp;raised his target price to $700 a share from $339 after changing how he thought about Tesla’s business. That was a huge target-price change from a large broker.</p><p><blockquote>早在1月份，加拿大皇家银行(RBC)分析师乔·斯帕克(Joe Spak)改变了对特斯拉业务的看法后，将目标价从每股339美元上调至700美元。对于一家大型经纪商来说，这是一个巨大的目标价格变化。</blockquote></p><p> Smaller changes in price targets can indicate a business is becoming more stable, and that analysts believe they have a grip on what is happening. That reduces the need for them to dramatically overhaul their views in response to events.</p><p><blockquote>价格目标的较小变化可能表明企业变得更加稳定，并且分析师相信他们能够控制正在发生的事情。这减少了他们在应对事件时大幅改变观点的必要性。</blockquote></p><p> Overall, the average&nbsp;analyst target price&nbsp;is up about $18, or 3%, in reaction to Monday’s results to about $644 a share. Tesla shares are trading about 1% or 2% above the average analyst target price.</p><p><blockquote>总体而言，针对周一的业绩，分析师平均目标价上涨约18美元，即3%，至每股约644美元。特斯拉股价比分析师平均目标价高出约1%或2%。</blockquote></p><p> Target prices generally reflect where analysts think a stock should trade to earn a fair return out into the future. The average target price on stocks in the S&amp;P 500 implies a gain of 7%.</p><p><blockquote>目标价格通常反映了分析师认为股票应该在哪里交易才能在未来获得公平回报。标普500股票的平均目标价意味着7%的涨幅。</blockquote></p><p> Even the fact that Tesla is trading around its average analyst target price is a sign of maturity. A year ago, the average target price for Tesla stock was about $225, while the price was above $300.</p><p><blockquote>即使特斯拉的交易价格在分析师平均目标价附近，也是成熟的标志。一年前，特斯拉股票的平均目标价约为225美元，而该价格高于300美元。</blockquote></p><p> Shareholders and bulls on the stock might like a bigger response from the stock when earnings come in strong, but the days of 20% moves, up or down, might be gone for Tesla. That is more evidence that Tesla is here to stay as the world’s most valuable car company.</p><p><blockquote>当盈利强劲时，该股的股东和看涨者可能希望该股做出更大的反应，但对于特斯拉来说，上涨或下跌20%的日子可能已经一去不复返了。这进一步证明特斯拉将继续成为世界上最有价值的汽车公司。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Is a Mature Business. Don’t Look Now.<blockquote>特斯拉是一项成熟的业务。现在别看。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Is a Mature Business. Don’t Look Now.<blockquote>特斯拉是一项成熟的业务。现在别看。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-07-27 22:47</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The electric-vehicle company&nbsp;Tesla&nbsp;reported its&nbsp;best quarterly results&nbsp;ever Monday evening, but investors and analysts are greeting the news with measured optimism—a sign that Tesla is maturing as a company.</p><p><blockquote>电动汽车公司特斯拉周一晚间公布了有史以来最好的季度业绩，但投资者和分析师对这一消息持谨慎乐观的态度——这表明特斯拉作为一家公司正在走向成熟。</blockquote></p><p> Tesla (ticker: TSLA)&nbsp;reported&nbsp;$1.45 in adjusted per-share earnings for the second quarter, far higher than the roughly 95 cents analysts were looking for. Sales from regulatory credits—a source of revenue seen as less sustainable than sales of vehicles—-fell, but operating profits rose to record highs because of strong profitability in the automotive division.</p><p><blockquote>特斯拉（股票代码：TSLA）公布第二季度调整后每股收益为1.45美元，远高于分析师预期的约95美分。监管信贷的销售额——一种被认为不如汽车销售可持续的收入来源——下降了，但由于汽车部门的强劲盈利能力，营业利润升至历史新高。</blockquote></p><p> Tesla generates the credits by making more than its fair share of zero- emission cars and sells them to manufacturers that still rely on internal-combustion engines. Pessimists on the stock believe that source of income will dwindle over time.</p><p><blockquote>特斯拉通过生产超过其公平份额的零排放汽车并将其出售给仍然依赖内燃机的制造商来产生积分。该股的悲观主义者认为，随着时间的推移，收入来源将会减少。</blockquote></p><p> The stock, however, was down 1.5% in early trading Tuesday. The&nbsp;S&amp;P 500&nbsp;and&nbsp;Dow Jones Industrial Average,for comparison, had fallen 0.6% and 0.4%, respectively.</p><p><blockquote>然而，该股周二早盘下跌1.5%。相比之下，标准普尔500指数和道琼斯工业平均指数分别下跌0.6%和0.4%。</blockquote></p><p> It is a muted reaction to a good quarter, typical of the way stocks of mature businesses behave. Tesla stock moved more than 10% in response to three of the four 2019 quarterly reports. But it rose or fell an average of about 2.5% in response to the 2020 earnings reports.</p><p><blockquote>这是对良好季度的温和反应，是成熟企业股票的典型表现。特斯拉股价因2019年四份季度报告中的三份而上涨超过10%。但随着2020年收益报告的发布，该指数平均上涨或下跌约2.5%。</blockquote></p><p> The typical 2020 move was a fall in the price in response to news of better-than-expected results. The same thing happened after the release of results for the first quarter of 2021.</p><p><blockquote>2020年的典型走势是因业绩好于预期的消息而导致价格下跌。同样的事情发生在2021年第一季度业绩发布后。</blockquote></p><p> That is another sign of maturity. A small drop in response to better-than-expected results is the typical outcome for stocks. Investors always expect companies to exceed analyst projections, and when they get that result, they “sell the news.”</p><p><blockquote>这是成熟的另一个标志。由于业绩好于预期而小幅下跌是股市的典型结果。投资者总是期望公司超出分析师的预测，当他们得到这个结果时，他们就会“卖出消息”。</blockquote></p><p> The reaction among Wall Street analysts to the latest results is yet another sign of maturity. Mizuho analyst&nbsp;Vijay Rakesh&nbsp;raised his target for Tesla’s stock price by $5 to $825 following the news, for a bump of less than 1%.</p><p><blockquote>华尔街分析师对最新业绩的反应是成熟的又一个迹象。消息传出后，瑞穗分析师Vijay Rakesh将特斯拉股价目标上调5美元至825美元，涨幅不到1%。</blockquote></p><p> Back in January, RBC analyst&nbsp;Joe Spak&nbsp;raised his target price to $700 a share from $339 after changing how he thought about Tesla’s business. That was a huge target-price change from a large broker.</p><p><blockquote>早在1月份，加拿大皇家银行(RBC)分析师乔·斯帕克(Joe Spak)改变了对特斯拉业务的看法后，将目标价从每股339美元上调至700美元。对于一家大型经纪商来说，这是一个巨大的目标价格变化。</blockquote></p><p> Smaller changes in price targets can indicate a business is becoming more stable, and that analysts believe they have a grip on what is happening. That reduces the need for them to dramatically overhaul their views in response to events.</p><p><blockquote>价格目标的较小变化可能表明企业变得更加稳定，并且分析师相信他们能够控制正在发生的事情。这减少了他们在应对事件时大幅改变观点的必要性。</blockquote></p><p> Overall, the average&nbsp;analyst target price&nbsp;is up about $18, or 3%, in reaction to Monday’s results to about $644 a share. Tesla shares are trading about 1% or 2% above the average analyst target price.</p><p><blockquote>总体而言，针对周一的业绩，分析师平均目标价上涨约18美元，即3%，至每股约644美元。特斯拉股价比分析师平均目标价高出约1%或2%。</blockquote></p><p> Target prices generally reflect where analysts think a stock should trade to earn a fair return out into the future. The average target price on stocks in the S&amp;P 500 implies a gain of 7%.</p><p><blockquote>目标价格通常反映了分析师认为股票应该在哪里交易才能在未来获得公平回报。标普500股票的平均目标价意味着7%的涨幅。</blockquote></p><p> Even the fact that Tesla is trading around its average analyst target price is a sign of maturity. A year ago, the average target price for Tesla stock was about $225, while the price was above $300.</p><p><blockquote>即使特斯拉的交易价格在分析师平均目标价附近，也是成熟的标志。一年前，特斯拉股票的平均目标价约为225美元，而该价格高于300美元。</blockquote></p><p> Shareholders and bulls on the stock might like a bigger response from the stock when earnings come in strong, but the days of 20% moves, up or down, might be gone for Tesla. That is more evidence that Tesla is here to stay as the world’s most valuable car company.</p><p><blockquote>当盈利强劲时，该股的股东和看涨者可能希望该股做出更大的反应，但对于特斯拉来说，上涨或下跌20%的日子可能已经一去不复返了。这进一步证明特斯拉将继续成为世界上最有价值的汽车公司。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/tesla-stock-mature-business-51627393369?mod=hp_LEADSUPP_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-stock-mature-business-51627393369?mod=hp_LEADSUPP_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124516451","content_text":"The electric-vehicle company Tesla reported its best quarterly results ever Monday evening, but investors and analysts are greeting the news with measured optimism—a sign that Tesla is maturing as a company.\nTesla (ticker: TSLA) reported $1.45 in adjusted per-share earnings for the second quarter, far higher than the roughly 95 cents analysts were looking for. Sales from regulatory credits—a source of revenue seen as less sustainable than sales of vehicles—-fell, but operating profits rose to record highs because of strong profitability in the automotive division.\nTesla generates the credits by making more than its fair share of zero- emission cars and sells them to manufacturers that still rely on internal-combustion engines. Pessimists on the stock believe that source of income will dwindle over time.\nThe stock, however, was down 1.5% in early trading Tuesday. The S&P 500 and Dow Jones Industrial Average,for comparison, had fallen 0.6% and 0.4%, respectively.\nIt is a muted reaction to a good quarter, typical of the way stocks of mature businesses behave. Tesla stock moved more than 10% in response to three of the four 2019 quarterly reports. But it rose or fell an average of about 2.5% in response to the 2020 earnings reports.\nThe typical 2020 move was a fall in the price in response to news of better-than-expected results. The same thing happened after the release of results for the first quarter of 2021.\nThat is another sign of maturity. A small drop in response to better-than-expected results is the typical outcome for stocks. Investors always expect companies to exceed analyst projections, and when they get that result, they “sell the news.”\nThe reaction among Wall Street analysts to the latest results is yet another sign of maturity. Mizuho analyst Vijay Rakesh raised his target for Tesla’s stock price by $5 to $825 following the news, for a bump of less than 1%.\nBack in January, RBC analyst Joe Spak raised his target price to $700 a share from $339 after changing how he thought about Tesla’s business. That was a huge target-price change from a large broker.\nSmaller changes in price targets can indicate a business is becoming more stable, and that analysts believe they have a grip on what is happening. That reduces the need for them to dramatically overhaul their views in response to events.\nOverall, the average analyst target price is up about $18, or 3%, in reaction to Monday’s results to about $644 a share. Tesla shares are trading about 1% or 2% above the average analyst target price.\nTarget prices generally reflect where analysts think a stock should trade to earn a fair return out into the future. The average target price on stocks in the S&P 500 implies a gain of 7%.\nEven the fact that Tesla is trading around its average analyst target price is a sign of maturity. A year ago, the average target price for Tesla stock was about $225, while the price was above $300.\nShareholders and bulls on the stock might like a bigger response from the stock when earnings come in strong, but the days of 20% moves, up or down, might be gone for Tesla. That is more evidence that Tesla is here to stay as the world’s most valuable car company.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":642,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807914992,"gmtCreate":1627996262216,"gmtModify":1631893653612,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"What. ePS?&nbsp;","listText":"What. ePS?&nbsp;","text":"What. ePS?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/807914992","repostId":"1124644819","repostType":4,"repost":{"id":"1124644819","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627995415,"share":"https://www.laohu8.com/m/news/1124644819?lang=zh_CN&edition=full","pubTime":"2021-08-03 20:56","market":"us","language":"en","title":"Nikola Q2 adj. per-share loss 20 cents, beats loss 30 cents estimate<blockquote>尼古拉Q2调整后。每股亏损20美分，超出预期30美分</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124644819","media":"Tiger Newspress","summary":"(August 3) Nikola Corporation Q2 adj. per-share loss 20 cents; FactSet loss consensus 30 cents.\nNiko","content":"<p>(August 3)&nbsp;<a href=\"https://laohu8.com/S/NKLA\">Nikola Corporation</a> Q2 adj. per-share loss 20 cents; FactSet loss consensus 30 cents.</p><p><blockquote>（8月3日）<a href=\"https://laohu8.com/S/NKLA\">尼古拉公司</a>Q2调整后。每股亏损20美分；FactSet损失共识30美分。</blockquote></p><p> Nikola Q2 per-share loss 36 cents vs. loss 43 cents a year ago.</p><p><blockquote>Nikola第二季度每股亏损36美分，而去年同期为亏损43美分。</blockquote></p><p> Nikola Q2 net loss 143.23&nbsp;bln vs. net loss 115.78&nbsp;bln a year ago.</p><p><blockquote>尼古拉第二季度净亏损1432.3亿美元，而去年同期净亏损1157.8亿美元。</blockquote></p><p> Nikola expects to deliver pre-series Tre BEVs for use on public roads in 2H2021.</p><p><blockquote>Nikola预计将于2021年下半年交付用于公共道路的预系列Tre纯电动汽车。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d1b990352dadc2e9c043eed4021bc904\" tg-width=\"4392\" tg-height=\"1316\" referrerpolicy=\"no-referrer\">\"During the second quarter Nikola continued to pave the way and solidify our place as a global leader in zero-emissions transportation solutions,” said Mark Russell, Nikola's Chief Executive Officer. “We have had continued success in commissioning and validating the Nikola Tre BEVs, completed both our Ulm, Germany and Phase 0.5 of our Coolidge, Arizona manufacturing facilities, entered into a purchase agreement with Tumim Stone Capital LLC for up to $300 million of Nikola common stock, and acquired a 20% stake in the Wabash Valley Resources clean hydrogen project in West Terra Haute, Indiana.”</p><p><blockquote>Nikola首席执行官Mark Russell表示：“第二季度，Nikola继续铺平道路，巩固我们作为零排放交通解决方案全球领导者的地位。”“我们在调试和验证Nikola Tre BEV方面持续取得成功，完成了德国乌尔姆和亚利桑那州柯立芝制造工厂的0.5阶段，与Tumim Stone Capital LLC签订了高达3亿美元的Nikola普通股购买协议，并收购了印第安纳州西特拉霍特Wabash Valley Resources清洁氢项目20%的股份。”</blockquote></p><p> <b>Business Outlook</b></p><p><blockquote><b>业务展望</b></blockquote></p><p> <ul>  <li>Nikola looks forward to achieving the following milestones in the second half of 2021:</li>  <li>Deliver pre-series Nikola Tre BEVs for use on public roads hauling customer freight;</li>  <li>Announce additional fleet testing customers/dealers;</li>  <li>Break ground on our first commercial hydrogen station and/or centralized hydrogen production facility; and</li>  <li>Announce additional hydrogen infrastructure/ecosystem partners</li> </ul> <b>Acquired 20% Interest in Wabash Valley Resources</b></p><p><blockquote><ul><li>尼古拉期待在2021年下半年实现以下里程碑：</li><li>交付预系列Nikola Tre纯电动汽车，用于在公共道路上运输客户货物；</li><li>宣布额外的车队测试客户/经销商；</li><li>我们的首个商业加氢站和/或集中制氢设施破土动工；和</li><li>宣布更多氢基础设施/生态系统合作伙伴</li></ul><b>收购沃巴什谷资源公司20%的权益</b></blockquote></p><p> On June 22, Nikola acquired a 20% equity interest in Wabash Valley Resources LLC (WVR), a clean hydrogen project being developed in West Terra Haute, Indiana in exchange for a $54.1 million cash and stock consideration. The project plans to use solid waste byproducts such as petroleum coke combined with biomass to produce clean and sustainable hydrogen. As part of the agreement, Nikola acquired the right to offtake up to 20% of the clean gaseous hydrogen produced at the facility at the anticipated price of less than $1.00 / kg*.</p><p><blockquote>6月22日，Nikola收购了Wabash Valley Resources LLC(WVR)20%的股权，这是一个正在印第安纳州West Terra Haute开发的清洁氢项目，以换取5410万美元的现金和股票对价。该项目计划利用石油焦等固体废物副产品与生物质结合生产清洁且可持续的氢气。作为协议的一部分，Nikola获得了以低于1.00美元/千克*的预期价格承购该工厂生产的高达20%的清洁气态氢气的权利。</blockquote></p><p> The offtake agreement with WVR could provide Nikola with approximately 50 tons of hydrogen per day following completion of the plant. This would allow us to supply clean hydrogen in a critical geography.</p><p><blockquote>与WVR的承购协议可在工厂建成后每天为Nikola提供约50吨氢气。这将使我们能够在关键地区供应清洁氢气。</blockquote></p><p> <b>Closed $300 Million Purchase Agreement with Tumim Stone Capital</b></p><p><blockquote><b>与Tumim Stone Capital达成3亿美元收购协议</b></blockquote></p><p> On June 11, Nikola entered into a common stock purchase agreement with Tumim Stone Capital LLC (Tumim), obligating Tumim to purchase up to $300 million of Nikola common stock. Under the agreement, Nikola has the right, but not the obligation to sell shares of its common stock to Tumim, subject to certain limitations. Purchase notices may be issued to Tumim over the period commencing from the date of the purchase agreement and ending on the first day of the month following the 36 months anniversary. The shares will be issued at a 3% discount to the three-day forward volume weighted average price (VWAP) from the date a purchase notice is issued.</p><p><blockquote>6月11日，Nikola与Tumim Stone Capital LLC(Tumim)签订了普通股购买协议，要求Tumim购买最多3亿美元的Nikola普通股。根据协议，Nikola有权但没有义务向Tumim出售其普通股，但须遵守某些限制。购买通知可在购买协议日期起至36个月周年纪念日下一个月的第一天止期间向Tumim发出。这些股票将以自购买通知发布之日起三天远期成交量加权平均价格(VWAP)的3%折扣发行。</blockquote></p><p> This allows us to sell shares to Tumim at our sole discretion and provides us with additional liquidity to execute on our business plan.</p><p><blockquote>这使我们能够自行决定向Tumim出售股票，并为我们提供额外的流动性来执行我们的业务计划。</blockquote></p><p> <a href=\"https://laohu8.com/S/NKLA\">Nikola Corporation</a>&nbsp;gained&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;premarket&nbsp;trading.</p><p><blockquote><a href=\"https://laohu8.com/S/NKLA\">尼古拉公司</a>盘前交易中上涨近2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3254115a823f409c5268ee517389b121\" tg-width=\"946\" tg-height=\"633\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nikola Q2 adj. per-share loss 20 cents, beats loss 30 cents estimate<blockquote>尼古拉Q2调整后。每股亏损20美分，超出预期30美分</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNikola Q2 adj. per-share loss 20 cents, beats loss 30 cents estimate<blockquote>尼古拉Q2调整后。每股亏损20美分，超出预期30美分</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-03 20:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(August 3)&nbsp;<a href=\"https://laohu8.com/S/NKLA\">Nikola Corporation</a> Q2 adj. per-share loss 20 cents; FactSet loss consensus 30 cents.</p><p><blockquote>（8月3日）<a href=\"https://laohu8.com/S/NKLA\">尼古拉公司</a>Q2调整后。每股亏损20美分；FactSet损失共识30美分。</blockquote></p><p> Nikola Q2 per-share loss 36 cents vs. loss 43 cents a year ago.</p><p><blockquote>Nikola第二季度每股亏损36美分，而去年同期为亏损43美分。</blockquote></p><p> Nikola Q2 net loss 143.23&nbsp;bln vs. net loss 115.78&nbsp;bln a year ago.</p><p><blockquote>尼古拉第二季度净亏损1432.3亿美元，而去年同期净亏损1157.8亿美元。</blockquote></p><p> Nikola expects to deliver pre-series Tre BEVs for use on public roads in 2H2021.</p><p><blockquote>Nikola预计将于2021年下半年交付用于公共道路的预系列Tre纯电动汽车。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d1b990352dadc2e9c043eed4021bc904\" tg-width=\"4392\" tg-height=\"1316\" referrerpolicy=\"no-referrer\">\"During the second quarter Nikola continued to pave the way and solidify our place as a global leader in zero-emissions transportation solutions,” said Mark Russell, Nikola's Chief Executive Officer. “We have had continued success in commissioning and validating the Nikola Tre BEVs, completed both our Ulm, Germany and Phase 0.5 of our Coolidge, Arizona manufacturing facilities, entered into a purchase agreement with Tumim Stone Capital LLC for up to $300 million of Nikola common stock, and acquired a 20% stake in the Wabash Valley Resources clean hydrogen project in West Terra Haute, Indiana.”</p><p><blockquote>Nikola首席执行官Mark Russell表示：“第二季度，Nikola继续铺平道路，巩固我们作为零排放交通解决方案全球领导者的地位。”“我们在调试和验证Nikola Tre BEV方面持续取得成功，完成了德国乌尔姆和亚利桑那州柯立芝制造工厂的0.5阶段，与Tumim Stone Capital LLC签订了高达3亿美元的Nikola普通股购买协议，并收购了印第安纳州西特拉霍特Wabash Valley Resources清洁氢项目20%的股份。”</blockquote></p><p> <b>Business Outlook</b></p><p><blockquote><b>业务展望</b></blockquote></p><p> <ul>  <li>Nikola looks forward to achieving the following milestones in the second half of 2021:</li>  <li>Deliver pre-series Nikola Tre BEVs for use on public roads hauling customer freight;</li>  <li>Announce additional fleet testing customers/dealers;</li>  <li>Break ground on our first commercial hydrogen station and/or centralized hydrogen production facility; and</li>  <li>Announce additional hydrogen infrastructure/ecosystem partners</li> </ul> <b>Acquired 20% Interest in Wabash Valley Resources</b></p><p><blockquote><ul><li>尼古拉期待在2021年下半年实现以下里程碑：</li><li>交付预系列Nikola Tre纯电动汽车，用于在公共道路上运输客户货物；</li><li>宣布额外的车队测试客户/经销商；</li><li>我们的首个商业加氢站和/或集中制氢设施破土动工；和</li><li>宣布更多氢基础设施/生态系统合作伙伴</li></ul><b>收购沃巴什谷资源公司20%的权益</b></blockquote></p><p> On June 22, Nikola acquired a 20% equity interest in Wabash Valley Resources LLC (WVR), a clean hydrogen project being developed in West Terra Haute, Indiana in exchange for a $54.1 million cash and stock consideration. The project plans to use solid waste byproducts such as petroleum coke combined with biomass to produce clean and sustainable hydrogen. As part of the agreement, Nikola acquired the right to offtake up to 20% of the clean gaseous hydrogen produced at the facility at the anticipated price of less than $1.00 / kg*.</p><p><blockquote>6月22日，Nikola收购了Wabash Valley Resources LLC(WVR)20%的股权，这是一个正在印第安纳州West Terra Haute开发的清洁氢项目，以换取5410万美元的现金和股票对价。该项目计划利用石油焦等固体废物副产品与生物质结合生产清洁且可持续的氢气。作为协议的一部分，Nikola获得了以低于1.00美元/千克*的预期价格承购该工厂生产的高达20%的清洁气态氢气的权利。</blockquote></p><p> The offtake agreement with WVR could provide Nikola with approximately 50 tons of hydrogen per day following completion of the plant. This would allow us to supply clean hydrogen in a critical geography.</p><p><blockquote>与WVR的承购协议可在工厂建成后每天为Nikola提供约50吨氢气。这将使我们能够在关键地区供应清洁氢气。</blockquote></p><p> <b>Closed $300 Million Purchase Agreement with Tumim Stone Capital</b></p><p><blockquote><b>与Tumim Stone Capital达成3亿美元收购协议</b></blockquote></p><p> On June 11, Nikola entered into a common stock purchase agreement with Tumim Stone Capital LLC (Tumim), obligating Tumim to purchase up to $300 million of Nikola common stock. Under the agreement, Nikola has the right, but not the obligation to sell shares of its common stock to Tumim, subject to certain limitations. Purchase notices may be issued to Tumim over the period commencing from the date of the purchase agreement and ending on the first day of the month following the 36 months anniversary. The shares will be issued at a 3% discount to the three-day forward volume weighted average price (VWAP) from the date a purchase notice is issued.</p><p><blockquote>6月11日，Nikola与Tumim Stone Capital LLC(Tumim)签订了普通股购买协议，要求Tumim购买最多3亿美元的Nikola普通股。根据协议，Nikola有权但没有义务向Tumim出售其普通股，但须遵守某些限制。购买通知可在购买协议日期起至36个月周年纪念日下一个月的第一天止期间向Tumim发出。这些股票将以自购买通知发布之日起三天远期成交量加权平均价格(VWAP)的3%折扣发行。</blockquote></p><p> This allows us to sell shares to Tumim at our sole discretion and provides us with additional liquidity to execute on our business plan.</p><p><blockquote>这使我们能够自行决定向Tumim出售股票，并为我们提供额外的流动性来执行我们的业务计划。</blockquote></p><p> <a href=\"https://laohu8.com/S/NKLA\">Nikola Corporation</a>&nbsp;gained&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;premarket&nbsp;trading.</p><p><blockquote><a href=\"https://laohu8.com/S/NKLA\">尼古拉公司</a>盘前交易中上涨近2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3254115a823f409c5268ee517389b121\" tg-width=\"946\" tg-height=\"633\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124644819","content_text":"(August 3) Nikola Corporation Q2 adj. per-share loss 20 cents; FactSet loss consensus 30 cents.\nNikola Q2 per-share loss 36 cents vs. loss 43 cents a year ago.\nNikola Q2 net loss 143.23 bln vs. net loss 115.78 bln a year ago.\nNikola expects to deliver pre-series Tre BEVs for use on public roads in 2H2021.\n\"During the second quarter Nikola continued to pave the way and solidify our place as a global leader in zero-emissions transportation solutions,” said Mark Russell, Nikola's Chief Executive Officer. “We have had continued success in commissioning and validating the Nikola Tre BEVs, completed both our Ulm, Germany and Phase 0.5 of our Coolidge, Arizona manufacturing facilities, entered into a purchase agreement with Tumim Stone Capital LLC for up to $300 million of Nikola common stock, and acquired a 20% stake in the Wabash Valley Resources clean hydrogen project in West Terra Haute, Indiana.”\nBusiness Outlook\n\nNikola looks forward to achieving the following milestones in the second half of 2021:\nDeliver pre-series Nikola Tre BEVs for use on public roads hauling customer freight;\nAnnounce additional fleet testing customers/dealers;\nBreak ground on our first commercial hydrogen station and/or centralized hydrogen production facility; and\nAnnounce additional hydrogen infrastructure/ecosystem partners\n\nAcquired 20% Interest in Wabash Valley Resources\nOn June 22, Nikola acquired a 20% equity interest in Wabash Valley Resources LLC (WVR), a clean hydrogen project being developed in West Terra Haute, Indiana in exchange for a $54.1 million cash and stock consideration. The project plans to use solid waste byproducts such as petroleum coke combined with biomass to produce clean and sustainable hydrogen. As part of the agreement, Nikola acquired the right to offtake up to 20% of the clean gaseous hydrogen produced at the facility at the anticipated price of less than $1.00 / kg*.\nThe offtake agreement with WVR could provide Nikola with approximately 50 tons of hydrogen per day following completion of the plant. This would allow us to supply clean hydrogen in a critical geography.\nClosed $300 Million Purchase Agreement with Tumim Stone Capital\nOn June 11, Nikola entered into a common stock purchase agreement with Tumim Stone Capital LLC (Tumim), obligating Tumim to purchase up to $300 million of Nikola common stock. Under the agreement, Nikola has the right, but not the obligation to sell shares of its common stock to Tumim, subject to certain limitations. Purchase notices may be issued to Tumim over the period commencing from the date of the purchase agreement and ending on the first day of the month following the 36 months anniversary. The shares will be issued at a 3% discount to the three-day forward volume weighted average price (VWAP) from the date a purchase notice is issued.\nThis allows us to sell shares to Tumim at our sole discretion and provides us with additional liquidity to execute on our business plan.\nNikola Corporation gained nearly 2% in premarket trading.","news_type":1,"symbols_score_info":{"NKLA":0.9}},"isVote":1,"tweetType":1,"viewCount":961,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":849880282,"gmtCreate":1635742012878,"gmtModify":1635742012952,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"Tesla will soon go for split again","listText":"Tesla will soon go for split again","text":"Tesla will soon go for split again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/849880282","repostId":"1164035523","repostType":2,"repost":{"id":"1164035523","kind":"news","pubTimestamp":1635736469,"share":"https://www.laohu8.com/m/news/1164035523?lang=zh_CN&edition=full","pubTime":"2021-11-01 11:14","market":"us","language":"en","title":"2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164035523","media":"Motley Fool","summary":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders h","content":"<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场寻求资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Growth Stocks That Could Deliver 1,000% Returns<blockquote>2只可带来1,000%回报的成长型股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-01 11:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist&nbsp;<b>Axsome Therapeutics</b>, the cancer specialist&nbsp;<b>Exelixis</b>, and the electric car pioneer&nbsp;<b>Tesla</b>&nbsp;have all delivered tenfold returns for investors who bought these names at their low points.</p><p><blockquote>由于科技和医疗保健领域持续的创新革命，股东在过去十年中一直享受着历史性的资本回报。例如，中枢神经系统疾病药物专家<b>轴体疗法</b>，癌症专家<b>Exelixis</b>，以及电动汽车先驱<b>特斯拉</b>都为在低点买入这些股票的投资者带来了十倍的回报。</blockquote></p><p> Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist&nbsp;<b>Mereo BioPharma Group</b>(NASDAQ:MREO)and the diabetes-focused medical device company&nbsp;<b>Senseonics Holdings</b>(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced&nbsp;healthcare stocks&nbsp;have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.</p><p><blockquote>从增长的角度来看，哪些股票可能成为下一个Axsome、Exelixis或特斯拉？癌症/罕见病专家<b>Mereo生物制药集团</b>（纳斯达克：MREO）和专注于糖尿病的医疗器械公司<b>Senseonics控股</b>(NYSEMKT：SENS)两者都可能很快就会为大幅走高做准备。事实上，这两只低价医疗保健股很有可能在未来两到三年内为股东带来1,000%以上的回报。</blockquote></p><p> Here's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.</p><p><blockquote>以下是与这些有前途的增长工具相关的风险和潜在回报的简要概述。</blockquote></p><p> <b>Mereo BioPharma: A bet on the future of immunotherapy</b></p><p><blockquote><b>Mereo BioPharma：押注免疫疗法的未来</b></blockquote></p><p> The London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.</p><p><blockquote>自其美国存托股票(ADS)在纳斯达克证券交易所首次亮相以来，总部位于伦敦的生物制药公司Mereo并没有真正引起轰动。与这一主题保持一致，自2019年4月以来，该生物技术公司的ADSE已损失约65%的价值。然而，这种稳定的下降趋势不应吓跑激进的投资者。毕竟，Mereo股价暴跌更多的是市场先生对临床阶段生物技术众所周知的不耐烦，而不是该公司的潜在价值主张。</blockquote></p><p> What's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the&nbsp;anti-TIGIT therapy&nbsp;known as etigilimab. Several major drug companies, such as&nbsp;<b>BeiGene</b>,<b>Bristol Myers Squibb</b>,<b>Merck</b>, and&nbsp;<b>Roche</b>, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.</p><p><blockquote>有什么独家新闻？Mereo是一家小型公司，拥有六项正在开发的癌症和罕见疾病资产。然而，一种无疑可能推动该公司股价飙升的候选药物是名为etigilimab的抗TIGIT疗法。几大药企，如<b>百济神州</b>,<b>百时美施贵宝</b>,<b>默克</b>，和<b>罗氏</b>由于抗TIGIT疗法通常具有增强癌症免疫疗法的功效和持久性的潜力，因此正在开发抗TIGIT疗法。Mereo的etigilimab目前正在进行一项联合1/2期篮子研究，以评估其作为联合治疗的一部分，与Bristol的megablockbuster检查点抑制剂Opdivo一起用于多种实体瘤。</blockquote></p><p> As things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.</p><p><blockquote>就目前情况而言，Mereo的抗TIGIT候选药物预计将在大约18个月后从这项篮子试验中产生顶线数据。然而，在这段漫长的时间间隔内，该制药商应该提供有关etigilimab进展的多项最新信息，这可能会成为未来几个月其股价的一系列主要催化剂。另一个好消息是，据报道Mereo的现金跑道将延伸至2024年。这是关键，因为这意味着生物技术公司不应该在未来一年半内反复利用公开市场寻求资本。</blockquote></p><p> What's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.</p><p><blockquote>下行风险是什么？Mereo的管理团队一直公开表示希望与大型生物制药公司合作。就Etigilimab而言，它可能会在未来两年内引发高额许可协议或全面收购。所以很大程度上取决于这种单一的实验药物。不幸的是，早期癌症疗法在临床上经常失败。由于这种情况下的失败将严重影响生物技术公司的股价，潜在投资者可能希望将初始头寸保持在较小的水平。</blockquote></p><p> <b>Senseonic: A rising tide lifts all boats</b></p><p><blockquote><b>Senseonic：水涨船高</b></blockquote></p><p> Senseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10%&nbsp;<i>per year</i>&nbsp;over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.</p><p><blockquote>Senseonics的股票值得超级激进的投资者关注，因为它拥有名为Eversense的植入式连续血糖监测(CGM)设备专营权。真相是CGM市场增长超过10%<i>每年</i>根据Grand View Research的一份报告，在过去五年中。更重要的是，该领域预计在未来五年内每年至少增长10%。对于像Senseonics这样的小型CGM参与者来说，这绝对是一个有利的趋势。</blockquote></p><p> So far, Senseonics has only captured a&nbsp;small sliver&nbsp;of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company&nbsp;submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.</p><p><blockquote>到目前为止，Senseonics仅凭借其Eversense特许经营权占领了这个价值数十亿美元的医疗设备市场的一小部分。但该公司希望通过食品和药物管理局(FDA)对其180天版本的Eversense CGM系统的潜在监管批准来大幅提高其竞争地位。该医疗器械公司一年多前就该拟议产品向FDA提交了监管申请。所以现在随时都可能做出决定。</blockquote></p><p></p><p> Why does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from&nbsp;<b>DexCom</b>&nbsp;and&nbsp;<b>Abbott Laboratories</b>, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.</p><p><blockquote>为什么FDA的批准很重要？Senseonics的内部预测显示，由于这一关键的监管批准，该公司的营收在未来五年内将以超过70%的复合年增长率增长。总而言之，目前的90天Eversense CGM系统在美国与市场领先的设备相比并没有特别的竞争力<b>DexCom</b>和<b>雅培实验室</b>，分别。但这种更耐用的设备版本可能会在未来几年导致销量飙升。</blockquote></p><p> What's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.</p><p><blockquote>有什么风险？Senseonics正在拥挤的空间中与许多资本雄厚的医疗设备巨头竞争。因此，这一期待已久的FDA批准有可能不会引发销售额的抛物线增长。这并不是对Senseonics CGM系统的打击，而是与拥有极其优越资源的医疗保健公司竞争的残酷现实。投资者不应忽视这一潜在的风险因素。</blockquote></p><p> All told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.</p><p><blockquote>总而言之，Senseonics可能正处于改变游戏规则的监管事件的边缘，这可能会成为该公司CGM特许经营权的一个关键转折点。如果属实，这家医疗器械公司的股票在这些水平上应该会非常便宜。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SENS":"Senseonics Holdings,Inc.","MREO":"Mereo Biopharma Group Plc"},"source_url":"https://www.fool.com/investing/2021/10/31/2-growth-stocks-that-could-deliver-1000-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164035523","content_text":"Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points.\nWhich stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist Mereo BioPharma Group(NASDAQ:MREO)and the diabetes-focused medical device company Senseonics Holdings(NYSEMKT:SENS)could both be gearing up for a monstrous run higher soon. In fact, these two low-priced healthcare stocks have a decent shot at generating 1,000%-plus returns for their shareholders within the next two to three years.\nHere's a brief overview on the risks and potential rewards associated with each of these promising growth vehicles.\nMereo BioPharma: A bet on the future of immunotherapy\nThe London-based biopharma Mereo hasn't exactly set the world on fire since its American depository shares (ADS) made their debut on the Nasdaq stock exchange. Keeping with this theme, the biotech's ADSes have lost approximately 65% of their value since April 2019. This steady downward trend shouldn't scare away aggressive investors, however. Mereo's plunging share price, after all, is more about Mr. Market's well-known impatience with clinical-stage biotechs, rather than the company's underlying value proposition.\nWhat's the scoop? Mereo is a small-cap company with six assets under development for both cancer and rare diseases. However, the one drug candidate that could undoubtedly send the company's shares rocketing higher is the anti-TIGIT therapy known as etigilimab. Several major drug companies, such as BeiGene,Bristol Myers Squibb,Merck, and Roche, have anti-TIGIT therapies under development due to their potential to boost the efficacy and durability of cancer immunotherapy treatments in general. Mereo's etigilimab is currently in a combined phase 1/2 basket study to evaluate its utility as part of combination treament, along with Bristol's megablockbuster checkpoint inhibitor Opdivo, for a variety of solid tumors.\nAs things stand now, Mereo's anti-TIGIT candidate is slated to yield top-line data from this basket trial in approximately 18-months from now. During this lengthy interval, however, the drugmaker ought to provide multiple updates on etigilimab's progress, which could turn out to be a series of major catalysts for its share price in the coming months. Another bit of good news is that Mereo's cash runway reportedly extends into 2024. That's key, because it means that the biotech shouldn't have to repeatly tap the public markets for capital over the next year and a half.\nWhat's the downside risk? Mereo's management team has been open about its desire to partner with larger biopharmas. Etigilimab, for its part, could spark either a high dollar licensing agreement or a full-on buyout within the next two years. So a lot is riding on this single experimental drug. Unfortunately, early stage cancer therapies fail more often than not in the clinic. As a failure in this case would weigh heavily on the biotech's share price, potential investors may want to keep any initial position on the small side.\nSenseonic: A rising tide lifts all boats\nSenseonics' stock is worth a look by ultra-aggressive investors due to its implantable continuous glucose monitoring (CGM) device franchise known as Eversense. The lowdown is that the CGM market has been growing by over 10% per year over the past five years, according to a report by Grand View Research. What's more, this space is forecast to grow by at least 10% per year over the next five years. That's definitely a favorable trend for a small-cap CGM player like Senseonics.\nSo far, Senseonics has only captured a small sliver of this multi-billion dollar medical device market with its Eversense franchise. But the company is hoping to drastically improve its competitive positioning with a potential regulatory approval by the Food and Drug Administration (FDA) for its 180-day version of the Eversense CGM system. The medical device company submitteda regulatory application to the FDA for this proposed product over a year ago. So a decision could come any day now.\nWhy does this FDA approval matter? Senseonics' internal projections have the company's top-line rising at a compound annual growth rate of over 70% over the next five years as a result of this key regulatory nod. The long and short of it is that the current 90-day Eversense CGM system isn't particularly competitive in the U.S. against the market-leading devices from DexCom and Abbott Laboratories, respectively. But this longer-lasting version of the device could cause sales to skyrocket in the coming years.\nWhat's the risk? Senseonics is competing in a jam-packed space against a number of well-capitalized medical-device giants. So there is a chance that this long-awaited FDA approval won't spark a parabolic rise in sales. That's not a knock against Senseonics' CGM system, but rather the harsh reality of competing against healthcare companies with vastly superior resources. Investors shouldn't ignore this potential risk factor.\nAll told, Senseonics could be on the verge of a game-changing regulatory event that might prove to be a key inflection point for the company's CGM franchise. If true, this medical device company's stock should turn out to be a downright bargain at these levels.","news_type":1,"symbols_score_info":{"MREO":0.9,"SENS":0.9}},"isVote":1,"tweetType":1,"viewCount":952,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":809264483,"gmtCreate":1627373588442,"gmtModify":1631893653631,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"Sales surge 98%???? Will stock price surge 10%????","listText":"Sales surge 98%???? Will stock price surge 10%????","text":"Sales surge 98%???? Will stock price surge 10%????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/809264483","repostId":"1117342739","repostType":4,"repost":{"id":"1117342739","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627373040,"share":"https://www.laohu8.com/m/news/1117342739?lang=zh_CN&edition=full","pubTime":"2021-07-27 16:04","market":"us","language":"en","title":"Tesla shares rose more than 1% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨超过1%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1117342739","media":"Tiger Newspress","summary":"Tesla Inc posted a bigger second-quarter profit than expected on Tuesday thanks to sharply higher sales of its less-expensive electric vehicles, as it raised prices to boost its margins on them.Tesla also cut costs which helped it offset many of the supply chain and microchip shortfalls facing the auto industry.For the first time since late 2019, Tesla profits did not rely on sales of environmental credits to other automakers, a sign of increasing financial health for the manufacturing operation","content":"<p>Tesla Inc posted a bigger second-quarter profit than expected on Tuesday thanks to sharply higher sales of its less-expensive electric vehicles, as it raised prices to boost its margins on them.</p><p><blockquote>特斯拉公司周二公布的第二季度利润高于预期，这要归功于其较便宜的电动汽车销量大幅增长，该公司提高了价格以提高其利润率。</blockquote></p><p> Tesla also cut costs which helped it offset many of the supply chain and microchip shortfalls facing the auto industry.</p><p><blockquote>特斯拉还削减了成本，这有助于抵消汽车行业面临的许多供应链和微芯片短缺问题。</blockquote></p><p> For the first time since late 2019, Tesla profits did not rely on sales of environmental credits to other automakers, a sign of increasing financial health for the manufacturing operation. Tesla boosted its performance by cutting features it said were unused or unneeded and raising U.S. vehicle prices.</p><p><blockquote>自2019年底以来，特斯拉的利润首次不依赖于向其他汽车制造商出售环境信用，这表明制造业务的财务状况日益健康。特斯拉通过削减其称未使用或不需要的功能以及提高美国汽车价格来提高其业绩。</blockquote></p><p> Shares of the world’s most valuable automaker rose more&nbsp;than&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>这家全球最有价值汽车制造商的股价在盘前交易中上涨超过1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/979d9a75ec94ed8bf291317150d11d05\" tg-width=\"900\" tg-height=\"639\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> In a call with investors and analysts, Tesla executives said that volume production growth will depend on parts availability, and Musk cautioned the shortage of semiconductors will continue.</p><p><blockquote>在与投资者和分析师的看涨期权中，特斯拉高管表示，量产增长将取决于零部件供应情况，马斯克警告称，半导体短缺将持续。</blockquote></p><p> “The global chip shortage situation remains quite serious,” Musk said.</p><p><blockquote>“全球芯片短缺的情况仍然相当严重，”马斯克说。</blockquote></p><p> Still, Musk said Tesla expects to launch production this year of the Model Y SUV at factories under construction in Texas and Germany. He said the company expects battery cell suppliers to double production next year.</p><p><blockquote>尽管如此，Musk表示，特斯拉预计今年将在德克萨斯和德意志的在建工厂投产Model Y SUV。他表示，该公司预计电池供应商明年的产量将翻一番。</blockquote></p><p> Despite the pandemic and the supply chain crisis, Tesla posted record deliveries during the quarter, thanks to sales of cheaper models including Model 3 sedans and Model Ys.</p><p><blockquote>尽管面临疫情和供应链危机，但得益于Model 3轿车和Model Y等更便宜车型的销售，特斯拉在本季度的交付量仍创下了纪录。</blockquote></p><p> The carmaker, led by billionaire entrepreneur Elon Musk, said revenue jumped to $11.96 billion from $6.04 billion a year earlier, when its California factory was shut down for more than six weeks due to local lockdown orders to fight the pandemic.</p><p><blockquote>这家由亿万富翁企业家埃隆·马斯克(Elon Musk)领导的汽车制造商表示，收入从一年前的60.4亿美元跃升至119.6亿美元，当时其加州工厂因当地抗击疫情的封锁令而关闭了六周多。</blockquote></p><p> Analysts had expected revenue of about $11.3 billion, according to IBES data from Refinitiv.</p><p><blockquote>根据Refinitiv的IBES数据，分析师此前预计营收约为113亿美元。</blockquote></p><p> Excluding items, Tesla posted a profit of $1.45 per share, easily topping analyst expectations for a profit of 98 cents per share.</p><p><blockquote>剔除项目后，特斯拉公布的每股利润为1.45美元，轻松超过分析师预期的每股98美分。</blockquote></p><p> Tesla said operating income rose with volume growth and cost reduction, which offset higher supply chain costs, lower regulatory credit revenue and other items including $23 million in losses on investment in cryptocurrency bitcoin.</p><p><blockquote>特斯拉表示，营业收入随着销量增长和成本降低而上升，这抵消了供应链成本上升、监管信贷收入下降和其他项目，包括加密货币比特币投资损失2300万美元。</blockquote></p><p> Tesla’s profitability has often relied on selling regulatory credits to other automakers, but in the second quarter, Tesla was profitable without these credits for the first time since the end of 2019. Its GAAP net income was $1.14 billion in the second quarter. Revenue from the credits only totaled $354 million.</p><p><blockquote>特斯拉的盈利能力通常依赖于向其他汽车制造商出售监管信用，但在第二季度，特斯拉自2019年底以来首次在没有这些信用的情况下实现盈利。其第二季度GAAP净利润为11.4亿美元。这些积分的收入总计仅为3.54亿美元。</blockquote></p><p> “Tesla impressed with its numbers, as most of its revenue came from vehicle sales,” Jesse Cohen, senior analyst at Investing.com, said.</p><p><blockquote>Investing.com高级分析师Jesse Cohen表示：“特斯拉对其数据印象深刻，因为其大部分收入来自汽车销售。”</blockquote></p><p> Carmaker Stellantis expects to achieve its European carbon dioxide (CO2) emissions targets this year without environmental credits bought from Tesla.</p><p><blockquote>汽车制造商Stellantis预计今年将在没有从特斯拉购买环境信用额的情况下实现其欧洲二氧化碳(CO2)排放目标。</blockquote></p><p> Tesla said it said it has delayed the launch of the Semi truck program to 2022 to focus on starting factories and due to limited availability of battery cells and other parts this year.</p><p><blockquote>特斯拉表示，由于今年电池和其他零部件的供应有限，该公司已将Semi卡车计划的启动推迟到2022年，以专注于启动工厂。</blockquote></p><p> But the company’s new 4680 batteries are not ready for volume production; executives said it was difficult to predict when technological challenges would be resolved.</p><p><blockquote>但该公司的新型4680电池尚未准备好量产；高管们表示，很难预测技术挑战何时会得到解决。</blockquote></p><p> In an aside, Musk said he “most likely will not be on earnings calls” going forward to discuss financial results with investors and analysts. These calls have been a colorful quarterly ritual Musk has used for discourses on Tesla technology, or to fire back at rivals or critics.</p><p><blockquote>顺便说一句，马斯克表示，他“很可能不会在财报评级上”与投资者和分析师讨论财务业绩。这些评级是马斯克每季度举行的一次丰富多彩的仪式，马斯克用它来讨论特斯拉技术，或者回击竞争对手或批评者。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla shares rose more than 1% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨超过1%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla shares rose more than 1% in premarket trading<blockquote>特斯拉股价在盘前交易中上涨超过1%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-27 16:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Tesla Inc posted a bigger second-quarter profit than expected on Tuesday thanks to sharply higher sales of its less-expensive electric vehicles, as it raised prices to boost its margins on them.</p><p><blockquote>特斯拉公司周二公布的第二季度利润高于预期，这要归功于其较便宜的电动汽车销量大幅增长，该公司提高了价格以提高其利润率。</blockquote></p><p> Tesla also cut costs which helped it offset many of the supply chain and microchip shortfalls facing the auto industry.</p><p><blockquote>特斯拉还削减了成本，这有助于抵消汽车行业面临的许多供应链和微芯片短缺问题。</blockquote></p><p> For the first time since late 2019, Tesla profits did not rely on sales of environmental credits to other automakers, a sign of increasing financial health for the manufacturing operation. Tesla boosted its performance by cutting features it said were unused or unneeded and raising U.S. vehicle prices.</p><p><blockquote>自2019年底以来，特斯拉的利润首次不依赖于向其他汽车制造商出售环境信用，这表明制造业务的财务状况日益健康。特斯拉通过削减其称未使用或不需要的功能以及提高美国汽车价格来提高其业绩。</blockquote></p><p> Shares of the world’s most valuable automaker rose more&nbsp;than&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>这家全球最有价值汽车制造商的股价在盘前交易中上涨超过1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/979d9a75ec94ed8bf291317150d11d05\" tg-width=\"900\" tg-height=\"639\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> In a call with investors and analysts, Tesla executives said that volume production growth will depend on parts availability, and Musk cautioned the shortage of semiconductors will continue.</p><p><blockquote>在与投资者和分析师的看涨期权中，特斯拉高管表示，量产增长将取决于零部件供应情况，马斯克警告称，半导体短缺将持续。</blockquote></p><p> “The global chip shortage situation remains quite serious,” Musk said.</p><p><blockquote>“全球芯片短缺的情况仍然相当严重，”马斯克说。</blockquote></p><p> Still, Musk said Tesla expects to launch production this year of the Model Y SUV at factories under construction in Texas and Germany. He said the company expects battery cell suppliers to double production next year.</p><p><blockquote>尽管如此，Musk表示，特斯拉预计今年将在德克萨斯和德意志的在建工厂投产Model Y SUV。他表示，该公司预计电池供应商明年的产量将翻一番。</blockquote></p><p> Despite the pandemic and the supply chain crisis, Tesla posted record deliveries during the quarter, thanks to sales of cheaper models including Model 3 sedans and Model Ys.</p><p><blockquote>尽管面临疫情和供应链危机，但得益于Model 3轿车和Model Y等更便宜车型的销售，特斯拉在本季度的交付量仍创下了纪录。</blockquote></p><p> The carmaker, led by billionaire entrepreneur Elon Musk, said revenue jumped to $11.96 billion from $6.04 billion a year earlier, when its California factory was shut down for more than six weeks due to local lockdown orders to fight the pandemic.</p><p><blockquote>这家由亿万富翁企业家埃隆·马斯克(Elon Musk)领导的汽车制造商表示，收入从一年前的60.4亿美元跃升至119.6亿美元，当时其加州工厂因当地抗击疫情的封锁令而关闭了六周多。</blockquote></p><p> Analysts had expected revenue of about $11.3 billion, according to IBES data from Refinitiv.</p><p><blockquote>根据Refinitiv的IBES数据，分析师此前预计营收约为113亿美元。</blockquote></p><p> Excluding items, Tesla posted a profit of $1.45 per share, easily topping analyst expectations for a profit of 98 cents per share.</p><p><blockquote>剔除项目后，特斯拉公布的每股利润为1.45美元，轻松超过分析师预期的每股98美分。</blockquote></p><p> Tesla said operating income rose with volume growth and cost reduction, which offset higher supply chain costs, lower regulatory credit revenue and other items including $23 million in losses on investment in cryptocurrency bitcoin.</p><p><blockquote>特斯拉表示，营业收入随着销量增长和成本降低而上升，这抵消了供应链成本上升、监管信贷收入下降和其他项目，包括加密货币比特币投资损失2300万美元。</blockquote></p><p> Tesla’s profitability has often relied on selling regulatory credits to other automakers, but in the second quarter, Tesla was profitable without these credits for the first time since the end of 2019. Its GAAP net income was $1.14 billion in the second quarter. Revenue from the credits only totaled $354 million.</p><p><blockquote>特斯拉的盈利能力通常依赖于向其他汽车制造商出售监管信用，但在第二季度，特斯拉自2019年底以来首次在没有这些信用的情况下实现盈利。其第二季度GAAP净利润为11.4亿美元。这些积分的收入总计仅为3.54亿美元。</blockquote></p><p> “Tesla impressed with its numbers, as most of its revenue came from vehicle sales,” Jesse Cohen, senior analyst at Investing.com, said.</p><p><blockquote>Investing.com高级分析师Jesse Cohen表示：“特斯拉对其数据印象深刻，因为其大部分收入来自汽车销售。”</blockquote></p><p> Carmaker Stellantis expects to achieve its European carbon dioxide (CO2) emissions targets this year without environmental credits bought from Tesla.</p><p><blockquote>汽车制造商Stellantis预计今年将在没有从特斯拉购买环境信用额的情况下实现其欧洲二氧化碳(CO2)排放目标。</blockquote></p><p> Tesla said it said it has delayed the launch of the Semi truck program to 2022 to focus on starting factories and due to limited availability of battery cells and other parts this year.</p><p><blockquote>特斯拉表示，由于今年电池和其他零部件的供应有限，该公司已将Semi卡车计划的启动推迟到2022年，以专注于启动工厂。</blockquote></p><p> But the company’s new 4680 batteries are not ready for volume production; executives said it was difficult to predict when technological challenges would be resolved.</p><p><blockquote>但该公司的新型4680电池尚未准备好量产；高管们表示，很难预测技术挑战何时会得到解决。</blockquote></p><p> In an aside, Musk said he “most likely will not be on earnings calls” going forward to discuss financial results with investors and analysts. These calls have been a colorful quarterly ritual Musk has used for discourses on Tesla technology, or to fire back at rivals or critics.</p><p><blockquote>顺便说一句，马斯克表示，他“很可能不会在财报评级上”与投资者和分析师讨论财务业绩。这些评级是马斯克每季度举行的一次丰富多彩的仪式，马斯克用它来讨论特斯拉技术，或者回击竞争对手或批评者。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117342739","content_text":"Tesla Inc posted a bigger second-quarter profit than expected on Tuesday thanks to sharply higher sales of its less-expensive electric vehicles, as it raised prices to boost its margins on them.\nTesla also cut costs which helped it offset many of the supply chain and microchip shortfalls facing the auto industry.\nFor the first time since late 2019, Tesla profits did not rely on sales of environmental credits to other automakers, a sign of increasing financial health for the manufacturing operation. Tesla boosted its performance by cutting features it said were unused or unneeded and raising U.S. vehicle prices.\nShares of the world’s most valuable automaker rose more than 1% in premarket trading.\n\nIn a call with investors and analysts, Tesla executives said that volume production growth will depend on parts availability, and Musk cautioned the shortage of semiconductors will continue.\n“The global chip shortage situation remains quite serious,” Musk said.\nStill, Musk said Tesla expects to launch production this year of the Model Y SUV at factories under construction in Texas and Germany. He said the company expects battery cell suppliers to double production next year.\nDespite the pandemic and the supply chain crisis, Tesla posted record deliveries during the quarter, thanks to sales of cheaper models including Model 3 sedans and Model Ys.\nThe carmaker, led by billionaire entrepreneur Elon Musk, said revenue jumped to $11.96 billion from $6.04 billion a year earlier, when its California factory was shut down for more than six weeks due to local lockdown orders to fight the pandemic.\nAnalysts had expected revenue of about $11.3 billion, according to IBES data from Refinitiv.\nExcluding items, Tesla posted a profit of $1.45 per share, easily topping analyst expectations for a profit of 98 cents per share.\nTesla said operating income rose with volume growth and cost reduction, which offset higher supply chain costs, lower regulatory credit revenue and other items including $23 million in losses on investment in cryptocurrency bitcoin.\nTesla’s profitability has often relied on selling regulatory credits to other automakers, but in the second quarter, Tesla was profitable without these credits for the first time since the end of 2019. Its GAAP net income was $1.14 billion in the second quarter. Revenue from the credits only totaled $354 million.\n“Tesla impressed with its numbers, as most of its revenue came from vehicle sales,” Jesse Cohen, senior analyst at Investing.com, said.\nCarmaker Stellantis expects to achieve its European carbon dioxide (CO2) emissions targets this year without environmental credits bought from Tesla.\nTesla said it said it has delayed the launch of the Semi truck program to 2022 to focus on starting factories and due to limited availability of battery cells and other parts this year.\nBut the company’s new 4680 batteries are not ready for volume production; executives said it was difficult to predict when technological challenges would be resolved.\nIn an aside, Musk said he “most likely will not be on earnings calls” going forward to discuss financial results with investors and analysts. These calls have been a colorful quarterly ritual Musk has used for discourses on Tesla technology, or to fire back at rivals or critics.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":747,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800474144,"gmtCreate":1627315625888,"gmtModify":1633766180863,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Always down most trading day, never up to $30 [Angry]&nbsp;[Angry]&nbsp;[Angry]&nbsp;[Angry]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>Always down most trading day, never up to $30 [Angry]&nbsp;[Angry]&nbsp;[Angry]&nbsp;[Angry]&nbsp;","text":"$Palantir Technologies Inc.(PLTR)$Always down most trading day, never up to $30 [Angry] [Angry] [Angry] [Angry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/800474144","isVote":1,"tweetType":1,"viewCount":1111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":879532663,"gmtCreate":1636734917800,"gmtModify":1636734917915,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Is this a falling knife stock?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Is this a falling knife stock?","text":"$BioNTech SE(BNTX)$Is this a falling knife stock?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/879532663","isVote":1,"tweetType":1,"viewCount":1985,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851463441,"gmtCreate":1634923042464,"gmtModify":1634923042700,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"Buy and treat as fixed deposit worry free stock","listText":"Buy and treat as fixed deposit worry free stock","text":"Buy and treat as fixed deposit worry free stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/851463441","repostId":"2177419115","repostType":2,"repost":{"id":"2177419115","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1634919955,"share":"https://www.laohu8.com/m/news/2177419115?lang=zh_CN&edition=full","pubTime":"2021-10-23 00:25","market":"hk","language":"en","title":"S&P Says Tesla Inc. Upgraded To 'BB+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive<blockquote>标准普尔表示，由于强劲的需求前景和稳健的财务指标，特斯拉公司将评级上调至“BB+”；展望积极</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2177419115","media":"T-Reuters","summary":"S&P:S&P Says Tesla Inc. Upgraded To 'Bb+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive.S&P, On Tesla, Says Positive Outlook Reflects Our View That Tesla'S Free Operating Cash Flow Generation Will Remain Positive More Consistently.S&P Says Despite Semiconductor Shortages, Other Supply-Related Bottlenecks, Tesla Appears To Have Minimized Production Disruption Versus Most Automakers.S&P Says View On Tesla Also Reflects Outperformance Of Electric Vehicles  So Far This Yea","content":"<p><html><body>S&amp;P:S&amp;P Says Tesla Inc. Upgraded To 'Bb+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive.S&amp;P, On Tesla, Says Positive Outlook Reflects Our View That Tesla'S Free Operating Cash Flow Generation Will Remain Positive More Consistently.S&amp;P Says Despite Semiconductor Shortages, Other Supply-Related Bottlenecks, Tesla Appears To Have Minimized Production Disruption Versus Most Automakers.S&amp;P Says View On Tesla Also Reflects Outperformance Of Electric Vehicles (Evs) So Far This Year Globally.S&amp;P Says Key Risks Going Forward Include Access To Supply As Tesla Looks To Raise Cell Capacity And Complete Its Production Ramp-Up To Meet Demand.S&amp;P Says Despite Near-Term Supply Bottlenecks For The Industry, We Expect Tesla Deliveries And Earnings To Remain Strong Over The Next Few Quarters.Further Company Coverage: Tsla.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</p><p><blockquote><html><body>标准普尔：标准普尔表示，由于强劲的需求前景和稳健的财务指标，特斯拉公司将评级上调至“Bb+”；前景积极。标准普尔在特斯拉表示，积极的前景反映了我们的观点，即特斯拉的自由运营现金流产生将更加持续地保持正值。标准普尔表示，尽管存在半导体短缺和其他与供应相关的瓶颈，但与大多数汽车制造商相比，特斯拉似乎已最大限度地减少了生产中断。标准普尔表示，对特斯拉的看法也反映了今年迄今为止全球电动汽车(EV)的优异表现。标准普尔表示，未来的主要风险包括获得供应，因为特斯拉希望提高电池产能并完成增产以满足需求。标准普尔表示，尽管该行业近期存在供应瓶颈，但我们预计特斯拉的交付量和盈利将在未来几个季度保持强劲。进一步的公司报道：Tsla.O。（（Reuters.Briefs@Thomsonreuters.Com；））。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P Says Tesla Inc. Upgraded To 'BB+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive<blockquote>标准普尔表示，由于强劲的需求前景和稳健的财务指标，特斯拉公司将评级上调至“BB+”；展望积极</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P Says Tesla Inc. Upgraded To 'BB+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive<blockquote>标准普尔表示，由于强劲的需求前景和稳健的财务指标，特斯拉公司将评级上调至“BB+”；展望积极</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time smaller\">2021-10-23 00:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>S&amp;P:S&amp;P Says Tesla Inc. Upgraded To 'Bb+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive.S&amp;P, On Tesla, Says Positive Outlook Reflects Our View That Tesla'S Free Operating Cash Flow Generation Will Remain Positive More Consistently.S&amp;P Says Despite Semiconductor Shortages, Other Supply-Related Bottlenecks, Tesla Appears To Have Minimized Production Disruption Versus Most Automakers.S&amp;P Says View On Tesla Also Reflects Outperformance Of Electric Vehicles (Evs) So Far This Year Globally.S&amp;P Says Key Risks Going Forward Include Access To Supply As Tesla Looks To Raise Cell Capacity And Complete Its Production Ramp-Up To Meet Demand.S&amp;P Says Despite Near-Term Supply Bottlenecks For The Industry, We Expect Tesla Deliveries And Earnings To Remain Strong Over The Next Few Quarters.Further Company Coverage: Tsla.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</p><p><blockquote><html><body>标准普尔：标准普尔表示，由于强劲的需求前景和稳健的财务指标，特斯拉公司将评级上调至“Bb+”；前景积极。标准普尔在特斯拉表示，积极的前景反映了我们的观点，即特斯拉的自由运营现金流产生将更加持续地保持正值。标准普尔表示，尽管存在半导体短缺和其他与供应相关的瓶颈，但与大多数汽车制造商相比，特斯拉似乎已最大限度地减少了生产中断。标准普尔表示，对特斯拉的看法也反映了今年迄今为止全球电动汽车(EV)的优异表现。标准普尔表示，未来的主要风险包括获得供应，因为特斯拉希望提高电池产能并完成增产以满足需求。标准普尔表示，尽管该行业近期存在供应瓶颈，但我们预计特斯拉的交付量和盈利将在未来几个季度保持强劲。进一步的公司报道：Tsla.O。（（Reuters.Briefs@Thomsonreuters.Com；））。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OLPX":"Olaplex Holdings, Inc.","TSLA":"特斯拉","HCTI":"Healthcare Triangle, Inc.","CRCT":"Cricut, Inc.","TERN":"Terns Pharmaceuticals, Inc.","FWRG":"First Watch Restaurant Group, Inc."},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177419115","content_text":"S&P:S&P Says Tesla Inc. Upgraded To 'Bb+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive.S&P, On Tesla, Says Positive Outlook Reflects Our View That Tesla'S Free Operating Cash Flow Generation Will Remain Positive More Consistently.S&P Says Despite Semiconductor Shortages, Other Supply-Related Bottlenecks, Tesla Appears To Have Minimized Production Disruption Versus Most Automakers.S&P Says View On Tesla Also Reflects Outperformance Of Electric Vehicles (Evs) So Far This Year Globally.S&P Says Key Risks Going Forward Include Access To Supply As Tesla Looks To Raise Cell Capacity And Complete Its Production Ramp-Up To Meet Demand.S&P Says Despite Near-Term Supply Bottlenecks For The Industry, We Expect Tesla Deliveries And Earnings To Remain Strong Over The Next Few Quarters.Further Company Coverage: Tsla.O. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1,"symbols_score_info":{"TERN":1,"HCTI":1,"TSLA":1,"CRCT":1,"OLPX":1,"ALVU":1,"FWRG":1}},"isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865058286,"gmtCreate":1632925862246,"gmtModify":1632925862458,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"But yesterday drop more then today little increase [Spurting]&nbsp;[Spurting]&nbsp;[Spurting]&nbsp;","listText":"But yesterday drop more then today little increase [Spurting]&nbsp;[Spurting]&nbsp;[Spurting]&nbsp;","text":"But yesterday drop more then today little increase [Spurting] [Spurting] [Spurting]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/865058286","repostId":"1190233990","repostType":4,"repost":{"id":"1190233990","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632925635,"share":"https://www.laohu8.com/m/news/1190233990?lang=zh_CN&edition=full","pubTime":"2021-09-29 22:27","market":"us","language":"en","title":"Pharmaceutical stocks rallied in morning trading<blockquote>医药股早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190233990","media":"Tiger Newspress","summary":"Pharmaceutical stocks rallied in morning trading.Pfizer,BioNTech SE,Eli Lilly,Merck,Moderna,AstraZen","content":"<p>Pharmaceutical stocks rallied in morning trading.Pfizer,BioNTech SE,Eli Lilly,Merck,Moderna,AstraZeneca&nbsp;and&nbsp;Sanofi&nbsp;climbed&nbsp;between 0.5% and 3%.</p><p><blockquote>医药股早盘上涨。辉瑞、BioNTech SE、礼来公司、默克、Moderna、阿斯利康和赛诺菲上涨0.5%至3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/30e27c112e85fc577e71ea58a8ac6216\" tg-width=\"407\" tg-height=\"716\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Pfizer’s covid-19 vaccine for kids may not be FDA authorized before november.</p><p><blockquote>辉瑞公司的儿童新冠肺炎疫苗可能不会在11月之前获得FDA的授权。</blockquote></p><p> Citi analyst Andrew Baum upgraded shares of Ely Lilly and Co&nbsp;to Buy and raised the price target.</p><p><blockquote>花旗分析师安德鲁·鲍姆将伊利礼来公司的股票评级上调至买入，并上调了目标价。</blockquote></p><p> Merck says its covid-19 antiviral pill is cctive against variants.</p><p><blockquote>默克公司表示，其新冠肺炎抗病毒药物对变种有效。</blockquote></p><p> AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal.</p><p><blockquote>阿斯利康以5亿美元的潜在交易收购罕见病制药商Caelum。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaceutical stocks rallied in morning trading<blockquote>医药股早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaceutical stocks rallied in morning trading<blockquote>医药股早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-29 22:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pharmaceutical stocks rallied in morning trading.Pfizer,BioNTech SE,Eli Lilly,Merck,Moderna,AstraZeneca&nbsp;and&nbsp;Sanofi&nbsp;climbed&nbsp;between 0.5% and 3%.</p><p><blockquote>医药股早盘上涨。辉瑞、BioNTech SE、礼来公司、默克、Moderna、阿斯利康和赛诺菲上涨0.5%至3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/30e27c112e85fc577e71ea58a8ac6216\" tg-width=\"407\" tg-height=\"716\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Pfizer’s covid-19 vaccine for kids may not be FDA authorized before november.</p><p><blockquote>辉瑞公司的儿童新冠肺炎疫苗可能不会在11月之前获得FDA的授权。</blockquote></p><p> Citi analyst Andrew Baum upgraded shares of Ely Lilly and Co&nbsp;to Buy and raised the price target.</p><p><blockquote>花旗分析师安德鲁·鲍姆将伊利礼来公司的股票评级上调至买入，并上调了目标价。</blockquote></p><p> Merck says its covid-19 antiviral pill is cctive against variants.</p><p><blockquote>默克公司表示，其新冠肺炎抗病毒药物对变种有效。</blockquote></p><p> AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal.</p><p><blockquote>阿斯利康以5亿美元的潜在交易收购罕见病制药商Caelum。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190233990","content_text":"Pharmaceutical stocks rallied in morning trading.Pfizer,BioNTech SE,Eli Lilly,Merck,Moderna,AstraZeneca and Sanofi climbed between 0.5% and 3%.\n\nPfizer’s covid-19 vaccine for kids may not be FDA authorized before november.\nCiti analyst Andrew Baum upgraded shares of Ely Lilly and Co to Buy and raised the price target.\nMerck says its covid-19 antiviral pill is cctive against variants.\nAstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":125980656,"gmtCreate":1624641103175,"gmtModify":1633950135573,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Bitcoin down Tesla down damn unlucky coin[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Speechless]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Bitcoin down Tesla down damn unlucky coin[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Speechless]&nbsp;[Sad]&nbsp;[Sad]&nbsp;[Sad]&nbsp;","text":"$Tesla Motors(TSLA)$Bitcoin down Tesla down damn unlucky coin[Sad] [Sad] [Sad] [Sad] [Sad] [Sad] [Speechless] [Sad] [Sad] [Sad]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/125980656","isVote":1,"tweetType":1,"viewCount":625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":864253013,"gmtCreate":1633114410754,"gmtModify":1633114411095,"author":{"id":"3560307510640662","authorId":"3560307510640662","name":"Youluyanglu","avatar":"https://static.tigerbbs.com/05bb06bcca1cb9cd5016f4c8230c2803","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3560307510640662","idStr":"3560307510640662"},"themes":[],"htmlText":"Her ETF is under performance after bill haung and her partner left .","listText":"Her ETF is under performance after bill haung and her partner left .","text":"Her ETF is under performance after bill haung and her partner left .","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864253013","repostId":"2172295185","repostType":4,"isVote":1,"tweetType":1,"viewCount":591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}